Early halt for new cancer drug trial after just 3 patients
NCT ID NCT05317078
Summary
This was a first-in-human study to test the safety and find the right dose of an experimental drug called AMG 794. It was for adults with advanced or metastatic cancers, like lung or ovarian cancer, that have a specific protein marker called claudin 6 (CLDN6). The trial was terminated early after enrolling only 3 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cabrini Hospital
Malvern, Victoria, 3144, Australia
-
City of Hope National Medical Center
Duarte, California, 91010, United States
-
Inselspital Bern
Bern, 3010, Switzerland
-
Monash Medical Centre
Clayton, Victoria, 3168, Australia
-
Southern Oncology Clinical Research Unit
Bedford Park, South Australia, 5042, Australia
-
University of California Irvine
Orange, California, 92868, United States
-
University of California Los Angeles
Los Angeles, California, 90095-1678, United States
-
Virginia Commonwealth University
Richmond, Virginia, 23219, United States
Conditions
Explore the condition pages connected to this study.